Scientists take aim at diabetes and obesity with exercise in a pill

March 23, 2017, Saint Louis University
John Walker, Ph.D., assistant professor of pharmacology and physiology at Saint Louis University and Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University Credit: Saint Louis University

With a series of new grants, Saint Louis University researchers will tackle the twin epidemics of diabetes and obesity by tapping into the potential of two nuclear receptors that control muscle metabolism. The scientists will optimize two promising drug compounds, moving a step closer toward capturing the benefits of exercise in pill form.

Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University, and John Walker, Ph.D., assistant professor of pharmacology and physiology at Saint Louis University, have received $2.4 million from the U.S. Department of Defense and $1.74 million from the National Institutes of Health in a series of grants that will fund the study of two receptors that are linked to muscle metabolism: REV-ERB and ERR.

In past studies, a developed by Burris that targets REV-ERB appears to act as an mimic. Genetic studies with ERR suggest that it may be a good target for development of exercise mimetic drugs as well.

Diabetes is the seventh leading cause of death in the U.S. and more than 80 percent of patients with type 2 diabetes are overweight or obese. Aiming to offer new options for patients suffering from the burdens of these health threats, Burris and Walker's work combines chemistry and biology to develop new treatments.

"We can design drugs rather than just study them," Burris said. "That's the fun part. We can take the work further toward developing new therapies."

Exercise provides health benefits that include improving insulin sensitivity and weight control. But not everyone is able to exercise.

"If you exercise, it's effectively a treatment for diabetes and obesity as you increase the metabolic rate of muscle," Burris said. "You develop a more efficient muscle. That's what you get from exercise. You develop more endurance and that is good for your metabolic function.

"Our drug compounds are doing similar things. They make muscles look like they're exercising, turning on the genes that get activated during exercise, even if no exercise is happening. Both studies operate this way."

In a 2013 New York Times article, Burris notes that while no drug is likely to recreate all of the health benefits of exercise, a pill could offer a way to reap the muscle metabolism benefits of exercise for people who are unable to exercise due to disability or ill health.

Burris and Walker study , which are signaling molecules that sense different hormone levels and regulate gene expression based on the signal they receive. The cancer drug tamoxifen, contraception, a heart failure drug and thyroid replacement therapy all work by targeting nuclear receptors.

"In many cases of illness, signaling is off," Burris said "And we can correct signals by dialing the hormone messages up or down, mimicking hormones or blocking them."

In both studies, researchers aim to optimize to dial up muscle metabolism.


Burris and his team were the first to use a synthetic agonist (a drug designed to turn the action up) for REV-ERB to show that it caused weight loss and improved in animals.

As the research team optimizes the drug for diabetes and obesity, they are looking to maximize some effects they've already noticed. In past studies, they've seen multiple benefits to the metabolic state, with improved cholesterol and reduced atherosclerosis, including some direct effects on plaques, and lower inflammation. They saw mice lose weight, even on high fat diets, use more oxygen, expend more energy and show greater endurance.

"Nuclear receptors are typically very good drug targets," Burris said. "However, because they control gene transcription, they are tricky. Though we want to discover how to turn a receptor up or down, it's important to find a ligand that won't do too much, which could cause side effects."

A key task for Walker - a chemist - is to prevent the drug from crossing the blood-brain barrier, the body's natural division that separates the brain from blood circulating in the body. This is the reverse challenge that many drug-designers face. Often, it's most difficult to help drugs intended to reach the brain cross the barrier.

However, in past studies, REV-ERB appeared to have effects on the brain, including decreasing anxiety. While researchers would like to tap the receptor's potential in the mental health arena as well, they also want to ensure that a drug designed to help obesity and diabetes is limited in its scope.

"The effects we see in the brain are not necessarily show-stoppers but since there are some, we want to try to stop the drug from reaching the brain," Burris said. "We don't necessarily want to decrease anxiety in someone who doesn't need it."

In addition to addressing the blood-brain barrier issue, Burris and Walker look to optimize the compound in other ways, including testing for any toxic properties and developing once-a-day dosing.


In the second study, Burris and Walker will optimize compounds that target a different receptor, ERR. ERR is an orphan receptor, meaning scientists don't know what its natural ligand is. A ligand is the molecule that binds to the receptor and regulates its activity. A few synthetic (man made) ligands have been created, but they are not yet perfected for use in disease models.

The SLU researchers will take this work further, aiming to develop methods to turn up the volume on ERR.

"We've designed some agonists to see what their effect is," Walker said. "Most of the data suggests that more ERR is better, the most useful in terms of muscle metabolism. These agonists look as though they'll be useful in models of obesity and diabetes."

In addition to showing promise for obesity and diabetes, the study will examine how improvements to muscle metabolism may affect muscular dystrophy.

Explore further: Researchers study a new way to lower LDL cholesterol

Related Stories

Researchers study a new way to lower LDL cholesterol

March 7, 2017
In a paper published in Biochemical Pharmacology, Saint Louis University researchers examined the way a nuclear receptor called REV-ERB is involved in regulating cholesterol metabolism. Their findings suggest that drugs targeting ...

Drug candidate leads to improved endurance

July 14, 2013
An international group of scientists has shown that a drug candidate designed by scientists from the Florida campus of The Scripps Research Institute (TSRI) significantly increases exercise endurance in animal models.

In lab research, scientists limit autistic behavior

December 2, 2015
In a study published this week in ACS Chemical Neuroscience, Saint Louis University researchers report that treating mice with a compound, SR1078, reduces autistic behavior. The drug, developed by Thomas Burris, Ph.D., chair ...

Researchers prevent type 1 diabetes in lab

January 20, 2015
In new research published in Endocrinology, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal ...

Drug stops fatty liver disease from causing inflammation, scarring

February 18, 2015
Doctors believe that up to 30 percent of the U.S. population may have fat accumulation in the liver, known as non-alcoholic fatty liver disease (NAFLD), that can lead to a range of damaging health consequences.

Whole-body vibration may be as effective as regular exercise

March 15, 2017
A less strenuous form of exercise known as whole-body vibration (WBV) can mimic the muscle and bone health benefits of regular exercise in mice, according to a new study published in the Endocrine Society's journal Endocrinology.

Recommended for you

New therapeutic avenue for type 2 diabetes

December 6, 2018
Restoring the action of insulin is one of the keys to fighting type 2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Université de Toulouse) are ...

Subtype of immune B cells can delay type 1 diabetes onset in mice

December 6, 2018
A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 ...

Is the pancreas regeneration debate settled? An original theory renewed

December 5, 2018
A contentious debate among diabetes researchers has surrounded the regeneration of pancreatic insulin-producing cells: not if these cells regenerate, but rather how.

One in four patients say they've skimped on insulin because of high cost

December 3, 2018
For patients with diabetes, insulin is a life-saving medicine and an essential component of diabetes management, yet in the past decade alone, the out-of-pocket costs for insulin have doubled in the United States. One-quarter ...

Parsing diabetic skin infections

December 3, 2018
People with diabetes are more susceptible to skin infection. According to a new study by C. Henrique Serezani, Ph.D., Stephanie Brandt, Ph.D., and colleagues, this susceptibility might be due to overabundance of a compound ...

Next step toward replacement therapy in type 1 diabetes

November 28, 2018
Scientists have discovered the signals that determine the fate of immature cells in the pancreas. The research shows that they are very mobile and that their destiny is strongly influenced by their immediate environment. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.